In addition to catching more harmful and aggressive cancers, contrast-enhanced mammography is less expensive, she says, and can be easily integrated into office workflow.
In recent years, healthcare—including radiology—has opened the door to more precision medicine strategies that rely on patient-specific information. In many cases, successful individualized care is supported by screening efforts. With breast cancer, these frequently include screening for breast cancer-related genes, mammographic density, family history of breast cancer, lifestyle, hormonal factors, and demographic data.
International research, published in the Journal of the National Cancer Institute, that involved more than 65,000 patients, Morris says, used 77 single nucleotide pleomorphisms, estrogen receptor status, and family history to create a polygenic risk score that determines a woman’s lifetime risk of developing breast cancer. For women with no family history, the lifetime risk is between 5.2% and 16.6%. Women with a first-degree family history have a lifetime risk range of 8.6% to 24.4%.
This polygenic risk score, she says, could be used clinically to more effectively inform targeted screening and prevention strategies. This shift away from more population-based screening to an increasingly personalized approach could help providers offer the most appropriate therapy methods earlier in the treatment process.